PetCure Oncology says it has treated 10,000 patients

PetCure Oncology says it has crossed the 10,000-patient mark, a milestone that underscores how much veterinary radiation oncology has changed over the past decade. In a January 7, 2026 company announcement, PetCure positioned the achievement as a sign that stereotactic radiation therapy is no longer confined mainly to academic hospitals or major metro referral centers, but is becoming more accessible through private specialty networks. That matters because access, convenience, and case selection have long shaped whether radiation is even part of the conversation for pet parents facing a cancer diagnosis. In public comments, PetCure chief medical officer Neal Mauldin has been especially direct on that point, arguing that the field has had to adapt to the reality that many families live hours from a radiation facility and are far more likely to pursue treatment when protocols can be completed in days rather than weeks. (petcureoncology.com)

The company’s own timeline helps show the pace of that expansion. PetCure announced its first 1,000 patients in September 2017, said it had treated more than 1,200 animals by late 2017, and reported 8,000 treated pets in April 2024. In that 2024 release, Thrive Pet Healthcare said most PetCure patients had received stereotactic radiation therapy, which delivers highly targeted doses in one to three sessions instead of the roughly 15 to 20 treatments associated with conventional protocols. More recent industry coverage has described the network as operating seven treatment centers plus one standalone comprehensive cancer care center. At the same time, PetCure has been previewing newer delivery models, including compact, self-contained radiation systems designed to treat some superficial, surgical-scar, and head-and-neck cases without the dedicated vault infrastructure required by traditional platforms. The company says those systems could eventually allow CT imaging, treatment planning, and treatment delivery during a single anesthetic event in selected patients. (petcureoncology.com)

PetCure’s core argument has been consistent: radiation therapy was historically hard to access in veterinary medicine, both geographically and operationally. The company says that when it was founded there were fewer than 70 traditional veterinary radiation therapy facilities in the U.S. The Veterinary Cancer Society’s current public facility listings still suggest a limited national footprint relative to the size of the companion animal cancer burden, and PetCure materials continue to point to an estimated 12 million annual cancer diagnoses in dogs and cats. In that context, a 10,000-patient milestone is less a market-saturation signal than a marker of how much unmet demand remains. PetCure’s leadership has linked that unmet demand directly to protocol design: if a family is 8 to 10 hours from a center, a two- to four-day stereotactic course may be feasible in a way that a three- to four-week conventional schedule is not. (petcureoncology.com)

The operational model is also part of the story. PetCure has built around referral partnerships, centralized expertise, and shorter-course therapy that may be easier for pet parents to accept than multiweek radiation schedules. Company job postings say the network includes 14 board-certified veterinary oncologists, while prior coverage described treatment planning being generated centrally in consultation with onsite teams. That structure has helped PetCure extend radiation services into private-practice settings that historically may not have supported full in-house radiation programs. Broader Thrive leadership has framed this as part of a more comprehensive oncology buildout, pairing radiation access with medical oncology and specialty training infrastructure rather than treating radiation as a standalone service line. (careers.thrivepetcare.com)

On the technology side, PetCure and Thrive signaled in late 2025 that they aren't done expanding. Their partnership with Empyrean Medical Systems will bring the Sirius advanced radiation platform to the Seattle market, with company leaders describing it as a step toward more precise, noninvasive treatment delivery. dvm360’s coverage of the announcement highlighted features such as robotic beam positioning, Monte Carlo-based treatment planning, and real-time image guidance. Those are company-backed claims rather than independent outcomes data, but they show where the network sees its next competitive edge: not just more locations, but newer hardware and workflow. PetCure has also outlined several areas it expects to shape radiation oncology in 2025 and beyond, including mobile or compact radiation systems, combinations of radiation and immunotherapy, broader use of low-dose radiation for chronic inflammatory disease, and low dose-rate radiation therapy as an adjunct in canine B-cell lymphoma treatment. (empyreanmed.com)

Expert reaction in the public record is limited, but PetCure’s own medical leadership has been explicit about the field’s direction. Chief medical officer Neal Mauldin has repeatedly emphasized stereotactic radiation’s ability to reduce treatment burden while maintaining precision, and earlier PetCure materials describe years of on-protocol treatment experience and data collection across thousands of cases. In more recent company commentary, Mauldin has also pointed to planned research combining radiation with immunotherapy in cats with oral squamous cell carcinoma, based on the idea that radiation may expose tumor antigens that can then be targeted by the immune system. PetCure has separately highlighted low-dose radiation therapy for nonmalignant inflammatory conditions including feline cystitis, stomatitis, and osteoarthritis in dogs and cats, as well as growing interest in low dose-rate radiation therapy for canine B-cell lymphoma, citing two peer-reviewed papers that reportedly found improved survival when it was incorporated into induction therapy. Independent public commentary from the broader industry has generally echoed the access theme: advanced oncology tools are becoming more available in private practice, even if they remain concentrated in specialty settings. (dvm360.com)

Why it matters: For veterinarians, this milestone is most useful as a signal about referral normalization. Radiation therapy, especially stereotactic protocols, is becoming easier to discuss when the treatment course is shorter, the referral center is closer, and the workflow between primary veterinarian, medical oncologist, and radiation team is more established. That doesn't make every cancer case a radiation case, and it doesn't resolve ongoing barriers around cost, travel, or case selection. But it does mean that for more patients, radiation is moving from "theoretical specialty option" to "realistic referral pathway." It may also mean that radiation’s role in practice expands at the margins, whether through combined-modality oncology studies, lower-dose protocols for chronic inflammatory disease, or more flexible delivery platforms that reduce infrastructure barriers. For practices trying to guide pet parents through oncology decisions, that shift can materially change what supportive counseling and treatment planning look like. (petcureoncology.com)

What to watch: The next meaningful developments will be whether PetCure adds new markets, whether newer platforms like Sirius measurably improve workflow or outcomes, and whether the company or outside investigators publish more robust comparative data on safety, local control, survival, and quality of life across tumor types. It will also be worth watching whether the company’s forward-looking themes for 2025—compact or mobile radiation systems, radiation-immunotherapy combinations, low-dose radiation for chronic inflammatory disease, and low dose-rate approaches in lymphoma—move from company vision to peer-reviewed clinical evidence and broader adoption. Until then, the 10,000-patient figure is best read as a business and access milestone, not a standalone clinical proof point. (empyreanmed.com)